Wedbush Forecasts Increased Earnings for Astria Therapeutics

Key Points

• Wedbush has increased its Q3 2025 EPS estimates for Astria Therapeutics to ($0.28) from a previous estimate of ($0.60), with the consensus for the full year now at ($1.65) EPS.
• Several research firms, including Citigroup and JMP Securities, have reaffirmed positive ratings and increased price targets for Astria Therapeutics, indicating a favorable outlook on its stock.
• Astria Therapeutics’ stock currently has a market cap of approximately $385.99 million and a price-to-earnings ratio of -3.38, reflecting significant market interest and activity among institutional investors.

Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Equities research analysts at Wedbush raised their Q3 2025 earnings per share estimates for shares of Astria Therapeutics in a research note issued to investors on Wednesday, August 13th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings per share of ($0.28) for the quarter, up from their prior estimate of ($0.60). The consensus estimate for Astria Therapeutics' current full-year earnings is ($1.65) per share. Wedbush also issued estimates for Astria Therapeutics' Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($1.97) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($1.95) EPS, FY2027 earnings at ($2.22) EPS, FY2028 earnings at ($1.54) EPS and FY2029 earnings at $2.19 EPS.

A number of other brokerages have also issued reports on ATXS. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Wednesday, August 13th. JMP Securities raised their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the stock a "market outperform" rating in a report on Wednesday, August 13th. Citigroup restated an "outperform" rating on shares of Astria Therapeutics in a report on Wednesday, August 13th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $47.00 price objective on shares of Astria Therapeutics in a report on Wednesday, May 14th. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $29.00.

Astria Therapeutics Price Performance

NASDAQ:ATXS traded up $0.01 during mid-day trading on Friday, reaching $6.31. The company's stock had a trading volume of 199,102 shares, compared to its average volume of 358,089. The company's fifty day simple moving average is $6.26 and its two-hundred day simple moving average is $5.73. Astria Therapeutics has a twelve month low of $3.56 and a twelve month high of $12.92. The stock has a market cap of $356.14 million, a P/E ratio of -3.14 and a beta of 0.48.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.04.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently modified their holdings of the stock. Fcpm Iii Services B.V. purchased a new stake in Astria Therapeutics during the 4th quarter worth approximately $25,680,000. JPMorgan Chase & Co. increased its holdings in shares of Astria Therapeutics by 4,607.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company's stock valued at $9,091,000 after acquiring an additional 1,660,039 shares during the last quarter. ADAR1 Capital Management LLC increased its holdings in shares of Astria Therapeutics by 605.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company's stock valued at $3,427,000 after acquiring an additional 550,706 shares during the last quarter. Nantahala Capital Management LLC grew its stake in Astria Therapeutics by 59.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 1,069,530 shares of the biotechnology company's stock worth $5,733,000 after buying an additional 400,000 shares during the last quarter. Finally, Vestal Point Capital LP grew its stake in Astria Therapeutics by 8.2% during the 2nd quarter. Vestal Point Capital LP now owns 4,522,000 shares of the biotechnology company's stock worth $24,238,000 after buying an additional 342,000 shares during the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.